Greiner Bio-One GmbH - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Greiner Bio-One GmbH


Greiner Bio-One GmbH

Greiner Bio-One is specialised in the development, production and distribution of plastic laboratory products. The company is a technology partner for universities, hospitals, research institutes and the diagnostic, pharmaceutical and biotechnology industries as well.

Greiner Bio-One GmbH is a division of Greiner Bio-One International AG, based in Kremsmuenster (Austria). Today Greiner Bio-One International AG generates a turnover of 364 million euros. It has over 1,700 employees and operates globally with 24 subsidiaries and numerous distributors in more than 100 countries.

Greiner Bio-One is a leading supplier of special products for cell cultures and microplates for high-throughput screening and a developer of innovative biochips and sample collection systems. The company performs contract work from the pharmaceutical industry, the diagnostic and medical sectors. Greiner Bio-One uses injection moulding to produce a whole range of customised plastic platforms for the life sciences sector and offers the complete product development and production process from the idea through to the finished product. The company produces small and large series, undertakes customer-specific branding and can call on production facilities in Europe, the U.S. and Asia.

Visit us at CPhI/ICSE/P-MEC Hall and stand number: Hall 4.1, Booth No. 41H09

Greiner Bio-One GmbH

Bad Haller Strasse 32, 4550 Kremsmuenster, Austria

Telephone: +43 7583 67910       Fax:  +43 7583 6318

E-mail: office@at.gbo.com

Website: www.gbo.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here